Acrivon Therapeutics, Inc. (ACRV)
(Delayed Data from NSDQ)
$7.95 USD
-0.16 (-1.97%)
Updated May 24, 2024 04:00 PM ET
After-Market: $7.92 -0.03 (-0.38%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACRV 7.95 -0.16(-1.97%)
Will ACRV be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ACRV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACRV
5 Small Drug Stocks to Buy From a Recovering Industry
Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year?
ACRV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season?
Catalyst (CPRX) to Report Q1 Earnings: What's in the Cards?
Other News for ACRV
Acrivon Therapeutics: A Buy Rating on Strong Clinical and Financial Prospects
ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics price target raised by $2 at H.C. Wainwright, here's why
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), Arcutis Biotherapeutics (ARQT) and TruBridge (TBRG)